Showing results (51-60 of 116) with videos related to

Sort By:
Pageof 12
Rheumatology and Therapy|March 18, 2024
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARERoy Fleischmann, Ricardo Blanco, Filip Van den Bosch, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 31, 2012
The burden of illness of osteoporosis in Canadian menJean-Eric Tarride, Na Guo, Robert Hopkins, et al.
Annals of the Rheumatic Diseases|August 1, 2019
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient responseRoy M Fleischmann, Mark C Genovese, Jeffrey V Enejosa, et al.
RMD Open|May 28, 2024
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE studyRoy Fleischmann, Jerzy Swierkot, Sara K Penn, et al.
Rheumatology and Therapy|December 18, 2021
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TofacitinibAra Dikranian, David Gold, Louis Bessette, et al.
The Journal of Rheumatology|March 3, 2016
How to Attract Trainees, a Pan-Canadian Perspective: Phase 1 of the "Training the Rheumatologists of Tomorrow" ProjectAlfred Cividino, Volodko Bakowsky, Susan Barr, et al.
RMD Open|February 5, 2022
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE studyRoy Fleischmann, Eduardo Mysler, Louis Bessette, et al.
Arthritis Research & Therapy|December 16, 2014
The presence of meniscal lesions is a strong predictor of neuropathic pain in symptomatic knee osteoarthritis: a cross-sectional pilot studyCamille Roubille, Jean-Pierre Raynauld, François Abram, et al.
Rheumatology and Therapy|April 10, 2026
Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN)Dara K Shahrokh, Ronald B Vender, Charles W Lynde, et al.
Therapeutic Advances in Musculoskeletal Disease|March 13, 2019
Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN studyLouis Bessette, Boulos Haraoui, Andrew Chow, et al.
Pageof 12